References in periodicals archive ?
Dr Frouws and her colleagues tell us that not only can aspirin prevent disease, but low dose aspirin is important as an adjunct therapy for gastrointestinal cancers.
The people who were aspirin resistant also had larger areas of the brain affected by the stroke, as measured by MRI diffusion weighted imaging, with infarct size of 2.
There was wide variation in inappropriate aspirin therapy depending on practice characteristics.
Identifying who can benefit from the colon cancer-reducing potential ofaspirin is an important step because in some patients aspirin causes an increasedrisk of stomach ulcers and gastrointestinal bleeding, researchers said.
These papers provide a strong argument for breast or prostate cancer patients to start taking aspirin and for colon cancer patients to either take aspirin or, since Liao et al.
However, the appropriate method for detecting aspirin resistance is still controversial and the absolute definition is not available.
What we have finally shown is that aspirin has a major preventative effect on cancer but this doesn't become apparent until years later.
But they say the new findings shift the risk-benefit balance in favour of aspirin, and could lead to a revision of medical guidelines.
With widespread use of aspirin for the treatment and prevention of cardiovascular disease, as well as for pain and fever, there is a need for an aspirin product that has improved gastrointestinal safety without reducing its effectiveness.
The study is believed to be the first to report a survival advantage among women with breast cancer who take aspirin.
Breast cancer survivors who take aspirin regularly may be less likely to die or have their cancer return, US researchers reported.